Lishur, thanks for your post. It brings up two very important issues.
First, that level of Paxlovid sales vividly illustrates how the market seems to have discounted the blockbuster potential for EDP-235. Now if ENTA can just get a partnership for EDP-235 so the phase 3 trials and begin to make this closer to a reality.
Second, the market seems to be ignoring the potential windfall for ENTA in this patent infringement suit.